These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 14750898)
1. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Esser M; Brunner H Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898 [TBL] [Abstract][Full Text] [Related]
2. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant. Goa KL; Bryson HM Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867 [TBL] [Abstract][Full Text] [Related]
3. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. Frampton JE; Faulds D Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371 [TBL] [Abstract][Full Text] [Related]
4. Colony-stimulating factors for the management of neutropenia in cancer patients. Dale DC Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591 [TBL] [Abstract][Full Text] [Related]
5. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. Pérez Velasco R J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168 [TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review. Barnes G; Pathak A; Schwartzberg L Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806 [TBL] [Abstract][Full Text] [Related]
8. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
9. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Rusthoven J; Bramwell V; Stephenson B Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631 [TBL] [Abstract][Full Text] [Related]
10. [Prevention and treatment of febrile neutropenia]. Montemurro F; Gallicchio M; Aglietta M Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724 [TBL] [Abstract][Full Text] [Related]
11. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. Messori A; Trippoli S; Tendi E J Clin Pharm Ther; 1996 Apr; 21(2):57-63. PubMed ID: 8809640 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371 [TBL] [Abstract][Full Text] [Related]
13. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany]. Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162 [TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies. Kath R; Hartmann M; Höffken K J Cancer Res Clin Oncol; 1998; 124(5):288-90. PubMed ID: 9645462 [TBL] [Abstract][Full Text] [Related]
16. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors]. Carrato A; Guillén-Ponce C; Grande-Pulido E Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851 [TBL] [Abstract][Full Text] [Related]
17. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Cosler LE; Calhoun EA; Agboola O; Lyman GH Pharmacotherapy; 2004 Apr; 24(4):488-94. PubMed ID: 15098803 [TBL] [Abstract][Full Text] [Related]